Does Atovaquone Increase QTc?
The effect of atovaquone on the QT interval is unknown in humans, according to the FDA drug label 1. There is no established evidence that atovaquone causes clinically significant QTc prolongation.
Evidence Assessment
FDA Drug Label Information (Highest Priority)
The official FDA labeling for atovaquone explicitly states: "The effect of atovaquone oral suspension on the QT interval is unknown in humans" 1. This is the most authoritative source available and indicates that formal QTc studies have not been conducted or have not demonstrated a clear effect.
Clinical Research Evidence
The only dedicated study examining atovaquone's cardiac effects found no evidence of cardiotoxicity. In 42 patients randomized to receive atovaquone-proguanil (either alone or combined with artesunate), electrocardiographic recordings at baseline and one hour after each dose showed no statistically significant change in QTc interval in either treatment group 2. This 2005 study specifically evaluated this question and found atovaquone to be safe from a cardiac standpoint.
Guideline Context
Current guidelines on QTc prolongation 3 emphasize monitoring for drugs known to prolong QTc, listing common culprits as the "anti's": antibiotics (macrolides and fluoroquinolones), antifungals, antiarrhythmics, antipsychotics/antidepressants, antiemetics, and miscellaneous agents including chloroquine. Atovaquone is notably absent from these lists of QTc-prolonging medications.
Clinical Implications
- Atovaquone does not require routine ECG monitoring for QTc prolongation when used in otherwise healthy patients
- It can be considered a safer alternative when QTc prolongation is a concern in patients requiring antimalarial or anti-Pneumocystis therapy
- Standard risk factors for QTc prolongation (electrolyte abnormalities, concomitant QTc-prolonging drugs, structural heart disease) should still be assessed as part of general patient care
Important Caveats
While atovaquone itself does not appear to prolong QTc, clinicians should remain vigilant about:
- Drug combinations: If atovaquone is used with other antimalarials or medications that do prolong QTc, standard monitoring applies
- Electrolyte disturbances: Patients with diarrhea, vomiting, or malabsorption may develop hypokalemia or hypomagnesemia independent of the drug
- Lack of formal thorough QT study: The absence of evidence is not definitive evidence of absence, though the available clinical data is reassuring
In summary, atovaquone can be used without specific concern for QTc prolongation based on current evidence, making it a reasonable choice when cardiac safety is a priority.